ECG
Everus Construction Group, Inc.
ECG has the edge over RKLB overall, supported by lower modeled downside and stronger valuation.
RKLB
Rocket Lab USA, Inc.
RKLB's outlook is improving, though it still trails on the overall score.
ECG Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Healthy |
ECG's revenue, profitability, cash flow and balance sheet are all currently healthy.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
ECG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $87.17 | — |
| Current | 15x | $87.17 | — |
| Cheap | 20x | $113 | +29% |
| Fair | 25x | $142 | +63% |
| Expensive | 31x | $174 | +100% |
Historical ranges are pointers, not guarantees.
ECG's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
ECG Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ECG, with profitability improving. However, they disagree widely on these estimates.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RKLB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
ECG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.78 | +20% |
| Q3 2026 | $5.66 | +60% |
| Q2 2026 | $4.98 | +53% |
| Q1 2026 | $4.37 | +47% |
| Q4 2025 | $3.95 | +35% |
| Q3 2025 | $3.54 | +37% |
| Q2 2025 | $3.25 | +31% |
| Q1 2025 | $2.98 | +20% |
| Q4 2024 | $2.92 | +19% |
ECG has the edge over RKLB on earnings quality, reporting a profit while its opponent remains loss making.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
ECG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +40% |
| Q2 2026 | $1.2B | +34% |
| Q1 2026 | $1B | +25% |
| Q4 2025 | $1B | +33% |
| Q3 2025 | $986.8M | +30% |
| Q2 2025 | $921.5M | +31% |
| Q1 2025 | $826.6M | +32% |
| Q4 2024 | $759.6M | +19% |
ECG's revenue has grown year over year for nine quarters in a row: $1.4B last quarter, up 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.8% | +1.5 points |
| Q2 2026 | 9.1% | +1.2 points |
| Q1 2026 | 7.5% | +1.3 points |
| Q4 2025 | 6.8% | +0.8 points |
| Q3 2025 | 7.3% | +0.3 points |
| Q2 2025 | 7.9% | +0.6 points |
| Q1 2025 | 6.2% | 0 points |
| Q4 2024 | 6.1% | -2 points |
ECG has the edge over RKLB on profitability, with a higher operating margin.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over ECG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
ECG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $52.7M | -20% |
| Q2 2026 | $33M | +169% |
| Q1 2026 | $128.2M | +$139.6M |
| Q4 2025 | $23.5M | -65% |
| Q2 2025 | $12.3M | +$37.7M |
| Q1 2025 | -$11.4M | -190% |
| Q4 2024 | $66.9M | -35% |
| Q2 2024 | -$25.4M | -$6M |
ECG has the edge over RKLB on cash generation, producing positive trailing cash flow while its opponent burns cash.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
ECG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +19K shares |
| 1 year | +0.2% | +102K shares |
| 3 years | +0.5% | +267K shares |
ECG has the edge over RKLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has 652M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ECG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2024 | 1.5x | Healthy |
| Q1 2024 | 0.0x | Very low |
| Q4 2023 | 0.9x | Very low |
ECG's net debt is less than a year of its operating earnings (EBITDA).
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ECG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 15.6 | Oversold |
ECG's weekly RSI is 36 (neutral) and its Stochastic is 16 (oversold).
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
ECG PE vs Industrials Sector
| Metric | ECG | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 24x | 36% below |
| PE % | 9 | 31 | 22 pts below |
ECG is trading at 15x earnings, a 36% discount to the Industrials sector's median of 24x.
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
ECG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.2 | 16% below |
| 20 week MA | $118.5 | 26% below |
| 50 week MA | $119.1 | 27% below |
| 100 week MA | $92.3 | 5.5% below |
RKLB has stronger trend alignment. ECG is above 0 of 4 weekly averages versus RKLB above 3 of 5.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB's trend is mixed: it's above three of its five weekly moving averages, and 104% above its 200-week average.
ECG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $52.5 | $69.9 | +33% |
| 2025 | $69.9 | $90.1 | +29% |
| 2026 YTD | $90.1 | $87.2 | -3.2% |
ECG has the edge over RKLB on returns for 2026, with the stronger performance.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB's yearly returns have swung widely, from +392% in 2024 to −69% in 2022. It's down 9.3% so far in 2026.